沙利度胺联合方案治疗晚期结直肠癌临床观察

Thalidomide-based Chemotherapy for Advanced Colorectal Cancer

目的探讨沙利度胺联合方案治疗晚期结直肠癌的疗效及安全性。方法 45例经病理证实的晚期结直肠癌患者随机分为治疗组和对照组。治疗组22例接受沙利度胺联合卡培他滨和奥沙利铂治疗,对照组23例仅接受卡培他滨联合奥沙利铂治疗。3周为1周期,至少2周期化疗,评价疗效。研究无进展生存期(PFS)、客观有效率(ORR)、疾病控制率(DCR),并观察安全性及不良反应。结果治疗组DCR为68.2%,而对照组为43.5%,差异有统计学意义(P<0.05),PFS、ORR及患者生活质量两组间差异无统计学意义(P>0.05)。结论沙利度胺联合方案治疗晚期结直肠癌可显著提高疾病控制率且耐受性良好,值得临床进一步研究。

Objective To analyze the efficacy and toxicities of the thalidomide-based chemotherapy on ad- vanced colorectal cancer. Methods A total of 45 patients pathologically confirmed with advanced colorec- tal cancer were randomly assigned to the treatment and control group. The treatment group （22 patients） was thalidomide combined with capecitabine plus oxaliplatin regimen and control group （23 patients） capecitabine plus oxaliplatin alone. The regimens were administered for more than 2 cycles （every 3 weeks） The research endpoints were progression-free survival（PFS）, objective response rate（ORR） as Well as disease control rate（DCR）. Drug safety and quality of life were also assessed. Results The DCR of the treatment group was higher than that of control group （68. 2% vs. 43. 5%,P〈0. 05）. The PFS and The ORR as well as the quality of life between 2 groups had no significant difference （P〈0. 05）. Conclusion The thalidomide-based chemotherapy on advanced colorectal cancer was well-tolerated and significantly improved the DCR, but PFS and ORR. It is worthy of further research in clinical practice.